0001209191-23-047971.txt : 20230901
0001209191-23-047971.hdr.sgml : 20230901
20230901164547
ACCESSION NUMBER: 0001209191-23-047971
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230901
DATE AS OF CHANGE: 20230901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandborn William J.
CENTRAL INDEX KEY: 0001923805
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40928
FILM NUMBER: 231233147
MAIL ADDRESS:
STREET 1: C/O VENTYX BIOSCIENCES, INC.
STREET 2: 662 ENCINITAS BLVD. STE 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ventyx Biosciences, Inc.
CENTRAL INDEX KEY: 0001851194
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832996852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12790 EL CAMINO REAL, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 945-2393
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-31
0
0001851194
Ventyx Biosciences, Inc.
VTYX
0001923805
Sandborn William J.
C/O VENTYX BIOSCIENCES, INC.
12790 EL CAMINO REAL, SUITE 200
SAN DIEGO
CA
92130
0
1
0
0
See Remarks
0
Common Stock
2023-08-31
4
M
0
11900
14.85
A
60289
D
Common Stock
2023-08-31
4
S
0
11900
33.6432
D
48389
D
Common Stock
24194
I
By Spouse
Stock Option (Right to Buy)
14.85
2023-08-31
4
M
0
11900
0.00
D
2032-05-09
Common Stock
11900
664300
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2022.
Represents the weighted average share price of an aggregate total of 11,900 shares sold in the price range of $33.35 to $34.1159. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022.
President and Chief Medical Officer
/s/ Christopher Krueger, as Attorney-in-Fact
2023-09-01